NovoCure IPO Stumbles Out of the Gate
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
NovoCure Ltd. (NASDAQ: NVCR) priced its initial public offering (IPO) of 12.5 million shares at $22 a share, sharply below the original anticipated range of $25 to $29 and even below a revised range of $23 to $24. Shares tumbled to an intra-day low Friday of $18.67, down more than 15% before staging a comeback to around $19.50. The stock opened at $20.16.
NovoCure is a commercial-stage oncology company developing a novel, proprietary therapy called TTFields for the treatment of solid tumor cancers. Joint bookrunners for the offering are JPMorgan, Deutsche Bank and Evercore Partners. Co-managers are Wells Fargo Securities, JMP Securities and Wedbush PacGrow. The underwriters have a 30-day option on an additional 1.125 million shares.
The company sold 7.5 million shares in the IPO and existing shareholders sold 5 million. NovoCure expected to receive $185.5 million in net proceeds at the midpoint of the revised range, if the underwriters took their full over-allotment options. The actual IPO price is about 6.4% below the midpoint of the revised range ($23.50). The $1.50 difference cost the company about $10.5 million, according information included in Thursday’s amended Form S-1 filing.
There were 14 health care IPOs globally in the third quarter, according to IPO ETF manager Renaissance Capital. Those IPOs raised a total of $2.1 billion, compared with a third quarter total of $5.4 billion in 2014 and a second quarter total this year of $4.9 billion. The three best performing of all 42 global IPOs in the quarter were health care companies, and two of the three worst performers were also health care companies.
In mid-afternoon trading, NovoCure’s shares traded down more than 13% at $19.07, in a first-day range of $18.67 to $20.48.
ALSO READ: 2 Deutsche Bank Health Care Focus Stocks With Big Upside Potential
Contact [email protected] for any questions or corrections.




